Valuation: Autolus Therapeutics plc

Market Cap 426M 374M 344M 321M 605M 40.48B 617M 4.14B 1.6B 19.87B 1.6B 1.56B 69.16B P/E 2026 *
-1.81x
P/E 2027 * -2.55x
Enterprise Value 386M 339M 312M 291M 549M 36.73B 560M 3.75B 1.45B 18.03B 1.45B 1.42B 62.74B EV / Sales 2026 *
3x
EV / Sales 2027 * 2.48x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week+0.31%
Current month-0.31%
1 month-13.32%
3 months+15.58%
6 months-14.71%
Current year-19.85%
1 week 1.55
Extreme 1.55
1.68
1 month 1.38
Extreme 1.38
1.84
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.7
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
03-18Other

Chief Executive Officer

6,917,877 4.1641%
03-18Other

Director

487,029 0.2932%
03-18Other

Director

265,000 0.1595%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+0.31%-30.35%-37.20% 426M
+0.86%+0.67%+17.33%-12.60% 63.44B
-1.56%+1.14%+54.57%+224.32% 56.98B
+0.36%+39.60%+39.60%+39.60% 41.58B
+3.16%+5.65%-50.57%-57.33% 38.01B
-1.84%+6.66%+63.67%-25.42% 31.9B
+4.83%+20.80%+154.41%-40.04% 27.79B
+1.37%+5.57%+66.59%+84.44% 22.65B
-0.56%+4.05%+1.53%+168.92% 17.64B
+1.34%-0.64%+64.17%+124.88% 16.49B
Average +0.70%+4.26%+38.09%+46.96% 31.69B
Weighted average by Cap. +0.63%+4.49%+40.50%+51.95%

Financials

2026 *2027 *
Net sales 129M 113M 104M 96.82M 183M 12.22B 186M 1.25B 484M 6B 483M 472M 20.88B 191M 168M 154M 144M 271M 18.16B 277M 1.86B 719M 8.91B 717M 702M 31.02B
Net income -242M -212M -195M -182M -343M -22.96B -350M -2.35B -910M -11.27B -907M -887M -39.23B -184M -161M -149M -138M -261M -17.47B -266M -1.79B -692M -8.58B -690M -675M -29.85B
Net Debt -39.53M -34.71M -31.95M -29.77M -56.14M -3.76B -57.28M -384M -149M -1.84B -148M -145M -6.42B 48.41M 42.51M 39.13M 36.46M 68.76M 4.6B 70.16M 471M 182M 2.26B 182M 178M 7.86B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
01/07/26 $1.595 -0.31% 391,548
30/06/26 $1.600 -3.03% 1,067,957
29/06/26 $1.650 +2.48% 959,824
26/06/26 $1.610 +1.26% 771,902
25/06/26 $1.590 0.00% 606,578
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.600USD
Average target price
8.550USD
Spread / Average Target
+434.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock